Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …

Orofacial pain is a universal predicament, afflicting millions of individuals worldwide.
Research on the molecular mechanisms of orofacial pain has predominately focused on the …

Objective Calcitonin gene–related peptide (CGRP) pathway inhibitors are emerging
treatments for migraine. CGRP‐mediated vasodilation is, however, a critical rescue …

Background erenumab was safe and effective in clinical trials for the prevention of migraine.
However, real-life data are still lacking. Here we report the clinical experience from an Italian …

Fremanezumab-vfrm (hereafter referred to as fremanezumab)[AJOVY™] is a fully
humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to …

Background Calcitonin gene‐related peptide has emerged as a therapeutic target in
migraine. Monoclonal antibodies and small molecule receptor antagonists (gepants) …

Purpose Transcranial direct current stimulation (tDCS) may have therapeutic potential in the
management of migraine. However, studies to date have yielded conflicting results. We …

Migraine is a common form of primary headache, affecting up to 1 in every 6 Americans. The
pathophysiology is an intricate interplay of genetic factors and environmental influence and …

α-Calcitonin gene-related peptide (α-CGRP) is a regulatory neuropeptide of 37 amino acids.
It is widely distributed in the central and peripheral nervous system, predominantly in cell …

Migraine headache is a common, chronic, debilitating disease with a complex etiology.
Current therapy for migraine headache comprises either treatments targeting acute migraine …